Literature DB >> 8752428

[Diffuse Lewy body disease].

K Kosaka1.   

Abstract

Diffuse Lewy body disease (DLBD), which we have proposed since 1976, has received great attention among both researchers and clinicians. Recently, it was reported by some English and American research groups that DLBD is the second most frequent dementing illness in the elderly, following Alzheimer-type dementia (ATD). Our recent research of 79 autopsied dementia cases in a hospital disclosed that DLBD (15.4%) was the second most common degenerative dementia, following ATD (43.6%). In 1980 we proposed Lewy body disease, and classified it into three types: brain stem type, transitional type, and diffuse type. Diffuse type of LBD is now called DLBD. In 1990 we divided DLBD into two forms: common form and pure form. The common form of DLBD has more or less Alzheimer pathology, and pure form has none. Very recently, we proposed the cerebral type of LBD, in which numerous Lewy bodies are found in the cerebral cortex and amygdala, but no PD pathology is present in the brain stem. Therefore, LBD is now classified as follows: [table: see text]

Entities:  

Mesh:

Year:  1995        PMID: 8752428

Source DB:  PubMed          Journal:  Rinsho Shinkeigaku        ISSN: 0009-918X


  3 in total

1.  Sequence variants in eukaryotic translation initiation factor 4-gamma (eIF4G1) are associated with Lewy body dementia.

Authors:  Shinsuke Fujioka; Christina Sundal; Audrey J Strongosky; Monica Case Castanedes; Rosa Rademakers; Owen A Ross; Carles Vilariño-Güell; Matthew J Farrer; Zbigniew K Wszolek; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2012-11-04       Impact factor: 17.088

2.  Parkin and PINK1 parkinsonism may represent nigral mitochondrial cytopathies distinct from Lewy body Parkinson's disease.

Authors:  J Eric Ahlskog
Journal:  Parkinsonism Relat Disord       Date:  2009-10-07       Impact factor: 4.891

3.  Alpha-synucleinopathy and neuropsychological symptoms in a population-based cohort of the elderly.

Authors:  Julia Zaccai; Carol Brayne; Fiona E Matthews; Paul G Ince
Journal:  Alzheimers Res Ther       Date:  2015-04-13       Impact factor: 6.982

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.